Regen BioPharma Q3 FY26 net loss widens to $637,785; revenue flat at $59,065
RGBP•Quarterly results
Regen BioPharma posted a net loss of $637,785 for the quarter ended June 30, 2026, widening 73.77% year over year.
Revenue was $59,065, unchanged from the year-earlier quarter.
Expenses and other costs
Operating expenses fell to $34,536 from $99,821, led by lower consulting and professional fees of $20,694.
Other expense deepened to $662,313 on derivative expense of $623,200.
Liquidity and going-concern warning
Cash was $239 at June 30, 2026; working capital deficit was about $5.9 million, with substantial doubt about going-concern status.
